Clinical Trials Logo

Clinical Trial Summary

This open-label, Phase IV prospective, observational study will evaluate patients, who have been diagnosed with Neovascular Age-Related Macular Degeneration and have previously received either a standard intravitreal injection of ranibizumab or aflibercept, in order to get and compare information regarding post-injection inflammatory (irritation in the eye)2-3 days post-injection.

Additionally, patients will be evaluated for visual acuity and pain 2-3 days post-injection.

THIS IS AN OBSERVATION STUDY AND NOT AN INTERVENTIONAL STUDY AS TO ENTER THIS STUDY SUBJECTS WILL HAVE HAD TO RECEIVED EITHER RANIBIZUMAB 0.5 MG OR AFIBERCEPT 2MG PRIOR TO ENTERING THE STUDY AND SIGNING CONSENT. THIS STUDY IS TO OBSERVE THE SUBJECT POST-INJECTION RECEIVED BEFORE ENTERING THIS STUDY.


Clinical Trial Description

Patients, age 65 to 90, with Neovascular Age-Related Macular Degeneration who present for treatment with intravitreal ranibizumab or aflibercept will be selected in this study. 300 subjects from one site in the United States will be enrolled. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01991730
Study type Observational
Source NJ Retina
Contact Daniel Roth, MD
Phone 732-220-1600
Email rothretina@gmail.com
Status Recruiting
Phase N/A
Start date October 2013

See also
  Status Clinical Trial Phase
Recruiting NCT03963817 - Snapshot Camera for AMD
Recruiting NCT04929756 - Eye Movement Rehabilitation in Low Vision Patients
Completed NCT04779398 - Association of MPOD Values With Blue Light.
Recruiting NCT03275753 - Visual Function Tests in Age-related Macular Degeneration
Recruiting NCT03609307 - Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial Phase 2/Phase 3
Completed NCT02909985 - Visual Activity Evoked by Infrared in Humans After Dark Adaptation N/A
Completed NCT02556723 - Intravitreal Injections of Ziv-aflibercept for Macular Diseases N/A
Active, not recruiting NCT01943396 - Treatment of AMD With Rheohemapheresis /RHF/ Phase 4
Completed NCT00963339 - Age-Related Macular Degeneration (AMD) - Usability Study N/A
Completed NCT00376701 - Combination Therapy for Age-Related Macular Degeneration. Phase 2
Recruiting NCT00347165 - Intravitreal Bevacizumab for Age-Related Macular Degeneration Phase 2
Completed NCT00800995 - Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD) Phase 3
Completed NCT04689789 - OCTA and Retinal Angiomatous Proliferation
Completed NCT02567604 - Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
Completed NCT02173496 - Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
Active, not recruiting NCT01657669 - Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results Phase 4
Completed NCT00791570 - Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy Phase 1
Completed NCT00776763 - Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab Phase 2
Completed NCT00413829 - Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB) Phase 2
Completed NCT00358345 - PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization Phase 4